Recent reports support a possible future application of gene expression profiling for the diagnosis of leukemias. However, the robustness of subtype-specific gene expression signatures has to be proven on independent patient samples. Here, we present gene expression data of 34 adult acute lymphoblastic leukemia (ALL) patients (Affymetrix U133A microarrays). Support Vector Machines (SVMs) were applied to stratify our samples based on given gene lists reported to predict MLL, BCR-ABL, and T-ALL, as well as MLL and non-MLL gene rearrangement positive pediatric ALL. In addition, seven other B-precursor ALL cases not bearing t(9;22) or t(11q23)/MLL chromosomal aberrations were analyzed. Using top differentially expressed genes, hierarchical cluster and principal component analyses demonstrate that the genetically more heterogeneous B-precursor ALL samples intercalate with BCR-ABL-positive cases, but were clearly distinct from T-ALL and MLL profiles. Similar expression signatures were observed for both heterogeneous B-precursor ALL and for BCR-ABL-positive cases. As an unrelated laboratory, we demonstrate that gene signatures defined for childhood ALL were also capable of stratifying distinct subtypes in our cohort of adult ALL patients. As such, previously reported gene expression patterns identified by microarray technology are validated and confirmed on truly independent leukemia patient samples.
Introduction
Acute lymphoblastic leukemias (ALLs) and acute myeloid leukemias (AMLs) are both heterogeneous diseases. 1 Several subtypes can be discriminated based on cytomorphology, immunophenotype, and recurrent chromosomal aberrations. Inspired by the pivotal discrimination of unselected ALL and AML samples based on their gene expression signatures, 2 recent microarray studies demonstrated the close correlation of immunophenotypical characteristics and chromosomal aberrations in prognostically important leukemia subtypes to distinct gene expression patterns. [3] [4] [5] [6] [7] The specific acute leukemia subtypes can be classified by gene expression signatures with exceedingly high accuracies. However, those findings are based on a limited number of patient samples or training and testing sets, respectively. More importantly, discriminative genes were validated based on expression profiles generated in one specific setting of an individual laboratory. In order to become generally accepted as an additional diagnostic method, the robustness of subtype-specific gene expression signatures for leukemia subclassification has to be proven on independent patient samples. We therefore asked the question whether differences in gene expression identified by other groups can also be used to differentiate our patient cohort.
Here, we analyzed the gene expression patterns (Affymetrix U133A microarrays) of our own cohort of 34 adult leukemia patients comprising precursor B-ALLs with MLL gene rearrangements (n ¼ 10), and translocation t(9;22) (n ¼ 15) as well as precursor T-ALLs (n ¼ 9). We applied the diagnostic compositions of candidate genes as reported by Yeoh et al 7 and Armstrong et al, 3 respectively, to stratify our cases. Thus, the aim of this study was to validate both the reported differentially expressed genes and to evaluate the applicability of pediatric gene expression signatures to predict adult ALL subtypes.
Secondly, we analyzed seven genetically more heterogeneous adult B-precursor ALL cases not bearing the above-mentioned chromosomal aberrations. Following a similar strategy, which was reported by Ferrando et al 8 for discovering novel oncogenes in T-ALL, the more heterogeneous B-precursor ALLs were projected into an ALL subtype relevant gene space.
Materials and methods

Patient samples
This study included bone marrow samples from n ¼ 41 adult ALL patients at diagnosis representing three distinct ALL subtypes MLL, BCR-ABL, and T-ALL, as well as heterogeneous B-precursor ALL cases (supplemental Table 1 ). All samples were sent between May 1999 and July 2002 for reference diagnostics to our laboratory and registered in our leukemia database. 9 Samples were received either locally or by overnight mail. Prior to therapy, all patients gave their informed consent for participation in the current evaluation after having been advised about the purpose and investigational nature of the study as well as of potential risks. The study design adhered to the declaration of Helsinki and was approved by the ethics committees of the participating institutions prior to its initiation. The diagnosis was performed by a combination of cytomorphology, cytogenetics, fluorescence in situ hybridization (FISH), multiparameterimmunophenotyping, and molecular genetics. A more detailed description of patient characteristics and the routine diagnostic procedures is included as supporting online information.
Microarray experiments and SVM classification
Microarray analyses were performed as previously described. 5, 6 In order to achieve comparability of differing sets of microarray expression data, the different Affymetrix U95A chip design and U133A chip design probeset information was matched. Briefly, we extracted and combined the significant U95Av2 probesets specific for MLL, BCR-ABL, and T-ALL subtypes as depicted in the respective publications. Unique U95Av2 probesets were then functionally annotated using the November 11, 2002 NetAffxt Analysis Center descriptions. 10 Next, we determined for those unique U95Av2 probesets their corresponding U133A counterparts. Genes represented on U95Av2 microarrays are also represented on U133A microarrays. However, due to the improvement of oligonucleotide selection for the U133A array design and the dynamic nature of public databases, probesets of different array designs are not identical. In order to identify the names of the probesets that are most closely related to another, Affymetrix has made comparison spreadsheets available (www.affymetrix.com). We therefore applied a stringent search strategy using the 'Human Genome U95 to Human Genome U133 Best Match comparison spreadsheet'. This search resulted in best-match U133A counterparts for the U95Av2 probesets, which were chosen for the following statistical analyses.
The classification accuracy of a given gene list for a set of microarray experiments was estimated using Support Vector Machines (SVMs) as supervised learning technique. In general, SVMs are trained on a subset of the data, in our study with prior knowledge using previously reported discriminative gene lists for the respective leukemia subtypes, and then this trained model is employed to assign new samples to known groups from a second and different data set. In our approach, the apparent accuracy, that is, the overall rate of correct predictions of the complete data set, was estimated by 10-fold crossvalidation. This means that the data set was divided into 10 approximately equally sized subsets; a SVM model was trained for nine subsets and predictions were generated for the remaining subset. This training and prediction process was repeated 10 times to include predictions for each subset.
Subsequently the data set was split into a training set, consisting of two-thirds of the samples, and a test set with the remaining one-third. The apparent accuracy for the training set was estimated by 10-fold crossvalidation (analogous to apparent accuracy for complete set). A SVM model of the training set was built to predict diagnosis in the independent test set, thereby estimating the true accuracy of the prediction model. This prediction approach was applied both for overall classification (multiclass) and binary classification (diagnosis X ) yes or no). For the latter, sensitivity and specificity were calculated: Sensitivity ¼ ðnumber of positive samples predictedÞ= ðnumber of true positivesÞ Specificity ¼ ðnumber of negative samples predictedÞ= ðnumber of true negativesÞ
More detailed information on U95A-U133A microarray probeset match strategy, applied statistical methods for data analysis, and classification, as well as raw gene expression intensities of diagnostic markers for download is included as supporting online information.
Supervised identification of differentially expressed genes
To identify the genes whose expression patterns best distinguished among T-ALL, MLL, and BCR-ABL-positive cases in our data series, we applied the SAM software program.
11 Affymetrix U133A signal intensities were transformed as previously described and subsequently inputted into the software. 5 A stringent cutoff for significance (tuning parameter delta) for o1 false-positive rated gene was chosen. A complete list of identified genes including the scaled microarray expression data is available in the online section.
Data visualization
To assess the similarity of gene expression patterns, we applied hierarchical cluster analysis and principal component analyses. 12, 13 Transformed U133A expression data were analyzed using the GeneMaths 2.01 software from Applied Maths, Belgium (cluster algorithm: Ward; selected coefficient: Euclidean distance).
Results and discussion
Genes identified by Yeoh et al and Armstrong et al were represented on Affymetrix HG-U95 chip design microarrays. Meanwhile, the newly designed HG-U133A microarray is available and was utilized for this study. According to the manufacturer's information, both oligonucleotide selection (for further details, see technical note on U133A array design, www.affymetrix.com) and analysis software (Microarray Suite 5.0) were improved compared to previous GeneChip microarrays. 14, 15 Additionally, sample assessment, handling and storage, differing target labeling protocols, microarray scanner photo multiplier tube settings, and different software algorithms for analysis of primary expression signal intensities (Microarray Suite software versions 4.0 vs 5.0) represent parameters that account for influences comparing the results from different laboratories. Taking all those pitfalls into account, we chose a simple strategy to compare different data sets of gene expression intensities. Briefly, according to Yeoh et al and Armstrong et al, respectively, all important U95 chip design candidate genes to discriminate ALL with MLL gene translocation, t(9;22)-positive ALL (BCR-ABL) and T-ALL were matched to our corresponding U133A probesets. The raw expression data were transformed as described (online supplemental material). Then we aimed at predicting our independent cohort of ALL patients using common machine learning algorithms (SVM) and a 10-fold crossvalidation approach. [16] [17] [18] ALL subtype prediction using St Jude Children's Research Hospital childhood ALL predictors First, we compared our expression data to available expression profiles (n ¼ 78) of St Jude Children's Research Hospital childhood ALL samples (http://www.stjuderesearch.org/data/ALL1). Yeoh et al had used Affymetrix oligonucleotide microarrays to analyze the pattern of genes expressed in leukemic blasts from 360 pediatric ALL patients. Distinct expression profiles identified each of the prognostically important leukemia subtypes, including T-ALL, E2A-PBX1, BCR-ABL, TEL-AML1, MLL gene rearrangement, and hyperdiploid 450 chromosomes. They selected discriminating genes for the various ALL subtypes using a variety of statistical metrics. We extracted and combined all significant U95Av2 probesets specific for MLL, BCR-ABL, and T-ALL subtypes. Next, we determined for those unique U95Av2 probesets their corresponding U133A counterparts.
The data presented here indicate that the genes reported by Yeoh et al can also separate our cohort of adult ALL patient samples. Subgroup prediction using SVM learning algorithms demonstrates the discriminative properties of those candidate genes specific for T-ALL, BCR-ABL, and MLL subtypes in ALL (Table 1) . A hierarchical cluster analysis of our adult ALL samples using the preselected subset of genes specific for MLL, BCR-ABL, or T-ALL confirms the capability of separating three ALL subtypes based on distinct expression signatures. As visualized in Figure 1 , samples of each of the three distinct ALL subtypes cluster together (upper dendrogram). Based on the given preselected gene expression data, the clustering algorithm accurately assigns the ALL samples according to their underlying genetic aberration and immunophenotype, respectively.
ALL subtype prediction using Dana-Farber Cancer Institute ALL predictors Secondly, we compared our expression data to available expression profiles of Dana-Farber Cancer Institute ALL samples (http://research.dfci.harvard.edu/korsmeyer/MLL.htm).
Armstrong et al compared the gene expression profiles of leukemic cells from individuals diagnosed with precursor B-ALL bearing an MLL gene rearrangement against those from patients diagnosed with conventional B-precursor ALL that lack this translocation (n ¼ 44 pediatric ALL patients). They had determined whether there were genes correlated with the presence of an MLL translocation. Here, we applied that set of published genes to distinguish between MLL and non-MLL cases in our cohort of patients. By applying this preselected set of marker genes, we can robustly distinguish between MLL and non-MLL leukemias in our cohort of adult patients with high accuracy ( Table 2 ). As visualized in Figure 2 , based on the given preselected U133A microarray gene expression data, the clustering algorithm accurately groups our ALL samples into MLL gene rearrangement positive and MLL gene rearrangement negative cases.
ALL subtype prediction using overlapping MLL-specific predictors
Finally, we can identify overlapping genes specific for MLL and non-MLL in both published data sets and apply this stringent marker selection to stratify MLL and non-MLL patient samples in our own cohort. A substantial number of genes characterizing MLL-positive patient samples are overlapping between Yeoh et al and Armstrong et al gene lists (see online supplemental section). In our microarray expression data set, leukemia classification using SVM learning algorithms demonstrates the accurate discriminative properties of those MLL-specific candidate genes (Table 3) . Again, based on the given preselected gene expression data, the clustering algorithm accurately groups our adult ALL samples into MLL gene rearrangement positive and MLL gene rearrangement negative cases (Figure 3 ). As such, in both pediatric and adult ALL patient cohorts, MLL gene rearrangement positive and MLL gene rearrangement negative cases can be robustly predicted.
Molecular characterization of heterogeneous B-precursor ALL cases
After obtaining these results, that specific signatures in childhood ALLs are also observed in adult ALLs, we were interested in the expression profiles of heterogeneous B-precursor ALL cases not positive for t(9;22) or t(11q23)/MLL, respectively. Therefore, we analyzed in addition seven B-precursor ALL patients (c-ALL and Pre-B-ALL) to gain new insights into the molecular features of these cases. This additional cohort comprised patients who showed a normal karyotype (n ¼ 2) or a variety of different karyotype abnormalities (n ¼ 5) (supplemental Table 1 ). A detailed description of respective immunophenotypes and karyotypes is available in the online section.
First an unsupervised analysis, that is hierarchical clustering and principal component analysis (PCA) of the complete data set, was performed. However, this analysis did not reveal informative structures (data not shown).
We therefore applied a supervised analysis using the SAM (significance analysis of microarrays) software to identify differentially expressed genes correlated to T-ALL, BCR-ABL, and MLL cases. 11 A selection of the top 510 genes accurately separated the latter three ALL subtypes in a respective principal component analysis (Figure 4a) . Next, other B-precursor ALL samples (without BCR-ABL or MLL chromosomal aberrations) were added to the data set and all cases were projected into the space of the 510 leukemia subtype relevant genes. As shown in Figure 4b , the other B-precursor ALL samples (yellow spheres) intercalate with BCR-ABL-positive samples (red spheres). Thus, the other B-precursor ALL shares similar characteristics with BCR-ABL-positive ALLs. This is in line with the definition and subclassification of B-precursor ALL according to EGIL, which based on the immunophenotype distinguishes Pro-B-ALL, common ALL, and Pre-B-ALL. 19 Most importantly, both other ALL cases and BCR-ABL cases belong to the common ALL and Pre-B-ALL groups, and are thus anticipated to have common gene expression profiles.
This finding can also be visualized using the hierarchical clustering technique ( Figure 5) . 12 As shown in Figure 5 , due to inherent similarities in their expression profiles three major branches of the top dendrogram can be observed. MLL and T-ALL samples are accurately grouped. The more heterogeneous Classification of an independent ALL cohort A Kohlmann et al
Figure 1
Hierarchical cluster analysis based on U133A microarray expression data of our adult ALL samples (columns) using a subset of genes (rows) identified to classify pediatric ALL samples (Yeoh et al). A total of 312 unique best-match U133A probesets were identified to represent the 364 unique U95Av2 probesets according to Yeoh et al for the distinction of MLL, BCR-ABL, and T-ALL leukemias. The normalized expression value for each gene is coded by color, with the scale shown at the lower left (s.d. from mean). Red cells indicate high expression and green cells indicate low expression. More detailed information on the genes, that is HGNC approved gene symbol and short functional description, is available as supporting online information. Classification of an independent ALL cohort A Kohlmann et al B-precursor ALL cases are exclusively distributed in the branch containing all BCR-ABL samples. Several subtrees in the left dendrogram indicate coexpression of genes for the distinct ALL subtypes. Subtree 1 contains genes overexpressed in T-ALL that have also recently been reported by other microarray studies: TRB, CD3D, CD3E, CD2, CD6, MAL, LCK, ITM2A, SH2D1A. 7, 8 A large number of these genes and additional candidates like transmembrane adapters (LAT, TRIM), further CD3 complex signal transducing members (CD3G, CD3Z), CD8A coreceptor, and ZAP70 tyrosine kinase could be correlated to a functional role in the class I MHC-restricted T-cell receptor signalosome. 20 As such, the identification of these overexpressed T-ALLassociated candidate genes illustrates the power of gene expression profiling to elucidate complex pathways in a highly parallel manner. Hierarchical cluster analysis based on U133A microarray expression data of our adult ALL samples (columns) using a subset of genes (rows) identified to classify pediatric ALL with MLL gene rearrangement and non-MLL, respectively (Armstrong et al). A total of 182 unique bestmatch U133A probesets corresponded to 217 identified U95A chip design probesets for the distinction of MLL and non-MLL ALL according to Armstrong et al. The normalized expression value for each gene is coded by color, with the scale shown at the lower left (s.d. from mean). Red cells indicate high expression and green cells indicate low expression. More detailed information on the genes, that is HGNC-approved gene symbol and short functional description, is available as supporting online information. Table 3 SVM subtype prediction accuracies using overlapping MLL-specific genes The distribution of cases in the training and test sets are: MLL (7, 3 cases), non-MLL (16, 8) .
Classification of an independent ALL cohort A Kohlmann et al Subtrees 4 and 5 group genes with a high expression in MLL gene rearranged positive ALLs. Also, genes that have recently been reported by other microarray studies were ADAM10, BLK, CD72, CD79A, CSPG4, HOXA9, HOXA10, IGHM, LGALS1, LMO2, MBNL, MEF2A, PPP2R5C, PTPRC, and VLDLR. 3, 7, 21 Candidate genes like IGHM, BLK, and CD79A illustrate the B-lineage characteristics of these cases, and an observed overexpression of HOXA cluster members illustrates important components of leukemogenesis driven by MLL gene translocations. (a) Principal component analysis of T-ALL (n ¼ 9), MLL (n ¼ 10), and BCR-ABL (n ¼ 15) patients. The leukemia samples are plotted in a three-dimensional space using the three components capturing most of the variance in the data set. Each patient sample is represented by a colorcoded sphere. Adult ALL cases are accurately separated based on 510 differentially expressed genes identified using the SAM software package. (b) Principal component analysis of T-ALL (n ¼ 9), MLL (n ¼ 10), BCR-ABL (n ¼ 15), and heterogeneous precursor B-lineage B-ALL (n ¼ 7) patients. The leukemia samples are plotted in a three-dimensional space using the three components capturing most of the variance in the data set. In all, 510 top differentially expressed genes have been identified using the SAM software package in a supervised approach considering the three entities T-ALL, MLL, and BCR-ABL. Each patient sample is represented by a color-coded sphere. Heterogeneous precursor B-lineage ALL samples (yellow spheres) intercalate with BCR-ABL-positive samples (red spheres) when projected in this ALL subtype-specific gene space.
II as well as HLA-DM and CD74 promotors, is a highly regulated transactivator governing all spatial, temporal, and quantitative aspects of MHC class II expression. 23 The chaperone CD74 (invariant chain) blocks the peptide-binding site of newly synthesized MHC class II molecules by its so-called CLIP fragment. 24 HLA-DM molecules catalyze the exchange of CLIP for antigenic peptides derived from endosomal compartments.
An interesting cluster of genes is organized in subtree 2, which is enlarged in Figure 6 . A total of 26 probesets demonstrate similar expression signatures for both BCR-ABLpositive and the more heterogeneous B-precursor cases. All candidate genes are consistently overexpressed in these cases compared to T-ALL and MLL samples. In detail, LGMN (legumain), also called asparaginyl endopeptidase (AEP), has been reported to be critically involved in the processing of antigens for MHC class II presentation. 25 More recently, a prodrug strategy incorporating a legumain-cleavable peptide substrate onto doxorubicin was developed. 26 A receptor tyrosine kinase activated by collagen, DDR1 (discoidin domain receptor 1), is represented by three probesets. In a recent report, highgrade primary brain and metastatic brain tumors showed unequivocal, intense DDR1 expression within the majority of tumor cells. 27 CD52, an excellent target for complementmediated lysis and antibody-dependent cellular cytotoxicity, has been identified by two probesets. Several clinical trials have already been carried out with Alemtuzumab (CAMPATH-1H), a humanized monoclonal antibody directed against the CD52 antigen of lymphocytes. 28 A cytokine-like protein (C17), retinoic acid induced gene (RAI14), or hypothetical protein LOC54103 represent further overexpressed genes. However, no functional gene annotation is available yet.
A similar distribution of the adult ALL samples can be observed when these cases were projected into the gene expression space of markers previously reported from Yeoh et al to discriminate six distinct pediatric ALL subtypes, that is T-ALL, E2A-PBX1, BCR-ABL, TEL-AML1, MLL, and hyperdiploid leukemias. 7 As anticipated, genetically heterogeneous samples again cluster together with BCR-ABL cases, confirming our previous observation. They do not show up as an independent fourth distinct cluster separated from adult T-ALL, MLL, and Hierarchical cluster analysis of T-ALL (n ¼ 9), MLL (n ¼ 10), BCR-ABL (n ¼ 15), and heterogeneous precursor B-lineage B-ALL (n ¼ 7) patients. This analysis is based on 510 differentially expressed genes, which have been identified using the SAM software package in a supervised approach considering the three entities T-ALL, MLL, and BCR-ABL. The normalized expression value for each gene is coded by color, with the scale shown at the lower left (s.d. from mean). Red cells indicate high expression and green cells indicate low expression. A more detailed information on the genes, that is HGNC-approved gene symbol and short functional description, is available as supporting online information.
Classification of an independent ALL cohort A Kohlmann et al BCR-ABL-positive leukemias. The observed dendrogram structure of a hierarchical cluster analysis, as well as a 3D plot from a principal component analysis, were added to the supplemental section (Supplemental Figure 1) . Thus, signatures, previously reported to correlate with E2A-PBX1, TEL-AML1, and hyperdiploid childhood leukemias could not separate these two groups. This is not unexpected as none of our heterogeneous Bprecursor ALL showed any of these genetic characteristics.
Conclusions
Taken together, our observations provide evidence that genes suitable for classification and prediction of childhood ALL are also capable of distinguishing the respective adult ALL subentities. This is a promising finding, as new molecular targets in common genetic subtypes of acute leukemias identified by microarray technology might be common therapeutic targets for both age groups of patients. Previously reported gene expression signatures identified by global genome expression analysis are validated and confirmed on a truly independent patient cohort. Despite influencing parameters such as technical equipment, different sample handling, routine diagnostic procedure, and target preparation for expression analysis by unrelated personnel in an independent diagnostic laboratory, it was demonstrated that ALLs can be classified and predicted based on microarray technology. A prospective validation of diagnostic compositions of candidate genes in clinical trials using less costly, low-density microarrays is warranted. Alternatively, a more minimalized set of discriminative genes may be tested in multiplex-PCR-based assays.
